Lorbrena

Active Ingredient(s): Lorlatinib
FDA Approved: * November 2, 2018
Pharm Company: * PFIZER INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lorbrena Overview

Lorlatinib (PF-6463922) is an anti-neoplastic drug developed by Pfizer. It is an orally-administered small molecule inhibitor of ROS1 and ALK. In 2015, FDA granted Pfizer orphan drug status for lorlatinib for the treatment of non-small cell lung cancer.[1] Lorlatinib is able to cross the blood-brain barrier.[2] Clinical studies Several clinical trials are ongoing. A phase II trial comparing avelumab alone and in combination with lorlatinib or crizotinib for...

Read more Lorbrena Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lorlatinib

Recent Lorbrena Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Lorbrena: (2 results)

Sorted by National Drug Code

• 0069-0227 Lorbrena 25 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
• 0069-0231 Lorbrena 100 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc

Other drugs which contain Lorlatinib or a similar ingredient: (1 result)

• LORLATINIB